Clinical Trial

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

Study acronym: 4CAST
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 15, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-26; most recent amendment 2025-05-12.
Status change: Not Yet Recruiting → Recruiting 2023-10-12
Trial Details
NCT Number NCT04947189
Lead Sponsor St Vincent's Hospital, Sydney
Conditions Triple Negative Breast Cancer
Enrollment 65 participants
Start Date 2022-11-01
Primary Completion 2026-07 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-15